| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02ad4c9403364a2277dc906d5bc5642e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6917
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2017-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44db26dc8b5a6c8b981839d61931efaf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2cbdb932fba87cd21ad3fb29f4ef2d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df298709883f198cefc90b5e579eed4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb0d770db6e616101b530069d55c9486 |
| publicationDate |
2019-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20190012747-A |
| titleOfInvention |
Pharmaceutical composition for preventing or treating of neurodegenerative diseases comprising HDL-ApoM-S1P as an active agent |
| abstract |
The present invention relates to a novel use of HDL-ApoM-S1P (high density lipoprotein supported on sphingosine-1-phosphate double-apoprotein M), and more particularly to a novel use of HDL-ApoM-S1P for degenerative brain diseases Improvement or treatment of cognitive disorders, learning and memory disorders, and cognitive, learning or memory-enhancing uses of HDL-ApoM-S1P. The HDL-ApoM-S1P of the present invention shows improvement effects on not only cognitive disorder, learning disorder and memory disorder but also amyloid beta and tau deposition as well as alleviation of nerve inflammation in degenerative brain diseases (especially Alzheimer's disease) Exhibit a considerably reduced effect. In addition, the increase of HDL-ApoM-S1P in the body shows an excellent cognitive, learning and memory-enhancing effect on normal subjects. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102200536-B1 |
| priorityDate |
2017-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |